WO2019119819A1 - 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 - Google Patents
一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 Download PDFInfo
- Publication number
- WO2019119819A1 WO2019119819A1 PCT/CN2018/099147 CN2018099147W WO2019119819A1 WO 2019119819 A1 WO2019119819 A1 WO 2019119819A1 CN 2018099147 W CN2018099147 W CN 2018099147W WO 2019119819 A1 WO2019119819 A1 WO 2019119819A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pluripotent stem
- stem cell
- placental pluripotent
- cell preparation
- placental
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
Definitions
- the invention relates to the field of acute lung injury treatment, in particular to the use of placental pluripotent stem cells in the treatment of acute lung injury and a preparation method thereof.
- Acute lung injury is mainly caused by gastric acid inhalation, infection, trauma, fat embolism, inhalation of toxic gases, etc., infection is the most common cause. Regardless of the cause of ALI, the inflammatory response plays a major role in its pathological changes. Although a large number of studies have attempted to elucidate the pathogenesis of ALI, no particularly effective treatments have been found to date. At present, the treatment of ALI is mainly based on supportive therapy, drug therapy and assisted ventilation therapy. It still maintains a high mortality rate in clinical practice, which is maintained at about 30% to 40%. Therefore, the development of effective ALI treatment drugs and means is very urgent.
- Placental pluripotent stem cells have the general phenotypic characteristics of mesenchymal stem cells and possess multi-directional differentiation potential. They also have the advantages of abundant sources, convenient materials, and strong proliferation ability in vitro. They are in the biomedical field such as tissue damage repair and disease treatment. A class of cells of great potential value.
- the object of the present invention is to provide a use of a placental pluripotent stem cell preparation for preparing a medicament for treating ALI, that is, a cell suspension preparation prepared by using placental pluripotent stem cells can reduce the degree of acute lung injury, improve lung function, and be a placental pluripotent Stem cells offer a new use.
- the technical solution adopted by the present invention is:
- the invention provides a use of a placental pluripotent stem cell preparation for preparing a medicament for treating acute lung injury (ALI).
- ALI acute lung injury
- placental pluripotent stem cell preparation is prepared as follows: the adherent cultured placenta pluripotent stem cells are digested with 0.25% trypsin-EDTA digestive juice, washed with physiological saline, and then suspended in physiological saline, that is, the placenta is more A stem cell preparation.
- placental pluripotent stem cells are adherently growing fibroblast-like cells expressing CD73, CD90 and CD105, and not expressing CD14, CD19, CD34, CD45 and HLA-DR.
- the placental pluripotent stem cells are derived from the fetal face of the neonatal placental tissue, separated by adherent culture by enzymatic digestion, and collected for 3-5 passages.
- the cell concentration in the placental pluripotent stem cell preparation is (2 to 6) ⁇ 10 7 /ml.
- the medicament is a medicament for treating acute lung pathological damage or treating lung function damage.
- the amount of the drug is (8 to 24) ⁇ 10 7 /kg body weight based on the number of placental pluripotent stem cells, and is intravenously infused.
- the infusion time of the cell suspension was 6 to 24 hours after modeling.
- the beneficial effects of the present invention are mainly embodied in: the present invention utilizes a mouse model of acute lung injury induced by lipopolysaccharide LPS, and demonstrates for the first time that intravenous injection of placental pluripotent stem cell preparation can significantly improve lung tissue damage in acute lung injury. Scoring and lung function impairments such as oxygen saturation and oxygenation index.
- Figure 1 shows the lung tissue structure and injury score map of each group
- A lung tissue HE staining
- B lung tissue damage score results
- Control ALI and PP respectively indicate normal group, ALI model group, ALI model placental pluripotent stem cells Injection group. ** indicates that the placenta pluripotent stem cell injection group was significantly different from the ALI model group (P ⁇ 0.01).
- Figure 2 is a graph showing the results of lung function indicators in each group; Control, ALI, and PP represent the normal group, the ALI model group, and the ALI model placental pluripotent stem cell injection group, respectively. * The placenta pluripotent stem cell injection group was significantly different from the ALI model group (P ⁇ 0.05). ** indicates that the placental pluripotent stem cell injection group was significantly different from the ALI model group (P ⁇ 0.01).
- Example 1 Preparation of a mouse model of acute lung injury
- mice were anesthetized by injecting 250 ⁇ l of 1% sodium pentobarbital (formed in PBS), and the skin and muscle layers were cut along the middle of the neck, and the trachea was exposed, and a 1 ml syringe was inserted into the center of the tracheal ring, and 2.5 mg/injection was injected.
- the LPS (in PBS) was administered at a dose of 10 mg/kg body weight.
- the mice were erected so that the solution was evenly distributed on both sides of the lungs. After suturing, the mice were normally fed in a sterile environment.
- Isolation and culture of placental pluripotent stem cells wash the surface of the placenta with physiological saline several times to remove impurities such as congestion and mucus, and then quickly disinfect the surface of the placenta with a 75% aqueous solution of ethanol, and then wash away the residual ethanol solution with physiological saline;
- the finished placenta is taken from the fetal tissue to a clean centrifuge tube and cut into a braided shape; a double volume of the enzyme solution (concentration of 300 IU/mL of type I collagenase + concentration of 40 IU/mL of DNase I, physiological saline is prepared) Digested at 37 ° C for 1 hour; the digestion product 70 ⁇ m filter was used to remove the tissue residue to obtain a cell suspension; the cell suspension was subjected to density gradient centrifugation with 1.077 g/ml Ficoll to separate monocytes, and physiologically The isolated mononuclear cells were washed 3 times with s
- Placental pluripotent stem cell flow identification P3 generation placental pluripotent stem cells, the number is about 1.0 ⁇ 10 6 , evenly divided into 9 tubes, centrifuged, resuspended to 200 ⁇ l with PBS, and washed twice. After centrifugation, leave 1 tube blank, and phenotypic labeling should be added according to one label per tube (antibody is mouse anti-human CD14-FITC, CD19-PE, CD29-FITC, CD34-PE, CD45-PE, HLA-DR- FITC, CD73-PE, CD90-PE and CD105-PE). Incubate in the dark room for 30 min, wash twice after centrifugation, then centrifuge and add 200 ⁇ l PBS to resuspend and measure by flow cytometry.
- antibody is mouse anti-human CD14-FITC, CD19-PE, CD29-FITC, CD34-PE, CD45-PE, HLA-DR- FITC, CD73-PE, CD90-PE
- step (1) 4th generation to about 90% confluent placental pluripotent stem cells, digested with 0.25% trypsin-EDTA, washed twice with physiological saline, suspended in physiological saline and adjusted to a concentration of 4 ⁇ 10 7 /ml That is the placental pluripotent stem cell preparation.
- Example 3 Infusion of placental pluripotent stem cell preparation reduces lung injury and improves lung function
- the mouse acute lung injury (ALI) model established by the method described in Example 1 was tested in three groups: group 1 was a normal group, group 2 was an ALI model group, and group 3 was an ALI model placental pluripotent stem cell preparation. Injection group.
- the group 3 was prepared by injecting the placental pluripotent stem cell preparation prepared in Example 2 through the tail vein at a dose of 8 ⁇ 10 7 /kg body weight 6 hours after modeling.
- the lung histopathology and blood gas analysis were performed at 90 h after injection to analyze the effect of placental pluripotent stem cells on ALI.
- lung pathological damage score was calculated in terms of the thickness of the alveolar wall.
- group 2 showed the pathological features of typical acute lung injury, alveolar structure destruction hemorrhage, alveolar wall thickening, inflammatory cell infiltration, and the degree of lung tissue damage in the placenta pluripotent stem cell preparation injection group was significantly reduced, showing alveolar Thinning of the wall, improvement of alveolar structure, and reduction of inflammatory cell infiltration (shown as A in Figure 1), lung injury scores showed significant differences in the pathological improvement of ALI in the placenta pluripotent stem cell preparation group. (As shown in B of Figure 1).
- blood gas analysis showed that placental pluripotent stem cell preparation injection can significantly improve blood oxygen saturation and oxygenation index, improve lung function (as shown in Figure 2).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
提供一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用，该胎盘多能干细胞来源于新生儿胎盘组织胎儿面部分，为贴壁生长的成纤维样细胞，表达CD73、CD90和CD105，不表达CD14、CD19、CD34、CD45和HLA-DR。
Description
本发明涉及急性肺损伤治疗领域，特别涉及胎盘多能干细胞在急性肺损伤治疗中的用途及其制备方法。
急性肺损伤(ALI)主要由胃酸吸入、感染、创伤、脂肪栓塞、吸入有毒气体等引起，感染是最常见原因。不论何种原因所致的ALI，炎症反应都在其病理改变中起了主要作用。虽然，大量的研究试图阐明ALI的发病机理，但是，至今仍没发现特别有效的治疗手段。目前，ALI的治疗上主要以支持治疗、药物治疗和辅助通气治疗为主，临床上仍然保持着很高的病死率，大约维持在30％～40％，因此开发有效的ALI治疗药物和手段十分迫切。
近年来，干细胞研究的蓬勃发展为组织工程和疾病治疗带来了新思路和希望。研究表明人胎盘组织中存在丰富的多能干细胞，可通过酶消化法或组织块贴壁法从新生儿胎盘组织中分离获得。胎盘多能干细胞具有间充质干细胞的一般表型特征，且拥有多向分化潜能，同时还具有来源丰富、取材方便、体外增殖能力强等优点，是在组织损伤修复和疾病治疗等生物医学领域极具潜在应用价值的一类细胞。
(三)发明内容
本发明的目的是提供一种胎盘多能干细胞制剂在制备治疗ALI药物中的用途，即利用胎盘多能干细胞制成的细胞悬液制剂能够降低急性肺损伤程度、改善肺功能，为胎盘多能干细胞提供了一种新用途。
为了解决上述技术问题，本发明采用的技术方案为：
本发明提供一种胎盘多能干细胞制剂在制备治疗急性肺损伤(ALI)药物中的应用。
进一步，所述胎盘多能干细胞制剂按如下方法制备：将贴壁培养的胎盘多能干细胞用0.25％胰蛋白酶-EDTA消化液进行消化，生理盐水洗涤后，再用生理盐水悬浮，即为胎盘多能干细胞制剂。
进一步，所述胎盘多能干细胞为贴壁生长的成纤维样细胞，表达CD73、CD90和CD105，不表达CD14、CD19、CD34、CD45和HLA-DR。胎盘多能干细胞来源于 新生儿胎盘组织胎儿面部分，通过酶消化法结合贴壁培养分离，收集3-5代细胞备用。
进一步，所述胎盘多能干细胞制剂中细胞浓度为(2～6)×10
7个/ml。
进一步，所述药物为治疗急性肺病理损伤或治疗肺功能损伤的药物。
所述药物用量以胎盘多能干细胞个数计为(8～24)×10
7个/kg体重，静脉输注。所述细胞悬液的输注时间为造模后的6～24小时。
与现有技术相比，本发明有益效果主要体现在：本发明利用脂多糖LPS诱导的急性肺损伤小鼠模型，首次证明通过静脉注射胎盘多能干细胞制剂能够显著改善急性肺损伤中肺组织损伤评分及血氧饱和度和氧合指数等肺功能损伤。
图1是各组肺组织结构及其损伤评分图；A，肺组织HE染色；B，肺组织损伤评分结果；其中Control、ALI和PP分别表示正常组、ALI模型组、ALI模型胎盘多能干细胞注射组。**表示胎盘多能干细胞注射组与ALI模型组比较差异极显著(P﹤0.01)。
图2是各组肺功能指标检测结果图；其中Control、ALI和PP分别表示正常组、ALI模型组、ALI模型胎盘多能干细胞注射组。*表示胎盘多能干细胞注射组与ALI模型组比较差异显著(P﹤0.05)，**表示胎盘多能干细胞注射组与ALI模型组比较差异极显著(P﹤0.01)。
下面结合具体实施例对本发明进行进一步描述，但本发明的保护范围并不仅限于此：
实施例1：急性肺损伤小鼠模型制备
小鼠注射250μl 1％戊巴比妥钠(PBS配制)进行麻醉，沿颈部中间剪开皮肤和肌肉层，暴露气管，用1ml注射器在气管两环中间向心方向刺入，注射2.5mg/ml的LPS(PBS配制)，剂量为10mg/kg体重，注射完成后即刻将小鼠竖立旋转，使得溶液均匀分布肺部两侧，缝合后，小鼠在无菌环境下正常饲喂。
实施例2：胎盘多能干细胞制剂
(1)胎盘多能干细胞分离培养和流式鉴定
胎盘多能干细胞分离培养：用生理盐水对胎盘表面清洗数次以去除淤血和粘液等杂质，再用体积浓度75％乙醇水溶液对胎盘表面进行快速消毒，后用生理盐水洗掉残余乙醇溶液；清洗完毕的胎盘取胎儿面组织至洁净离心管中，并 剪碎成糜状；加入2倍体积的酶溶液(浓度300IU/mL的Ⅰ型胶原酶+浓度40IU/mL的DNA酶I，生理盐水配制)，于37℃下消化1小时；消化产物70μm滤网过滤去除其中的组织残渣，得到细胞悬液；将细胞悬液用1.077g/ml的Ficoll进行密度梯度离心，分离单核细胞，用生理盐水将分离到的单个核细胞洗涤3次；用α-MEM培养液(添加体积浓度均为1％的青霉素、链霉素、两性霉素B和谷氨酰胺，以及体积浓度为15％胎牛血清，α-MEM培养液购自Invitrogen公司)悬浮细胞，以1×10
6/cm
2密度接种至75cm
2塑料细胞培养瓶中，置于37℃、饱和湿度、含5％CO
2培养箱中培养，48h后倾倒除去未贴壁细胞，换新鲜培养液，而后每2～3天换液，待细胞长至90％汇合时，消化传代，P3～5代细胞收集备用。
胎盘多能干细胞流式鉴定：取P3代胎盘多能干细胞，数量约为1.0×10
6，分别均匀分装成9管，离心后用PBS重悬至200μl，洗涤2次。离心后留1管做空白，表型标记按每管一个标记进行添加(抗体分别为小鼠抗人CD14-FITC、CD19-PE、CD29-FITC、CD34-PE、CD45-PE、HLA-DR-FITC、CD73-PE、CD90-PE和CD105-PE)。暗室孵育30min，离心后洗涤2次，然后离心后加200μl PBS重悬，流式细胞仪测定。
表1 胎盘多能干细胞流式检测结果
(2)胎盘多能干细胞制剂的制备
取步骤(1)第4代长至90％左右汇合的胎盘多能干细胞，0.25％胰蛋白酶-EDTA消化，生理盐水洗涤2次后，用生理盐水悬浮并调整浓度至4×10
7个/ml，即为胎盘多能干细胞制剂。
实施例3：胎盘多能干细胞制剂输注降低肺损伤程度、改善肺功能
(1)利用实施例1所述方法建立的小鼠急性肺损伤(ALI)模型，实验为3组：组1为正常组、组2为ALI模型组、组3为ALI模型胎盘多能干细胞制剂注射 组。3组于建模后6h，按8×10
7个/kg体重剂量通过尾静脉输注实施例2制备的胎盘多能干细胞制剂。注射后90h取样进行肺组织病理学和血气分析检测，分析胎盘多能干细胞对ALI的作用效果。
(2)肺组织病理学检测：取肺组织，置于4％多聚甲醛中4度固定过夜，而后进行石蜡切片以及HE染色，显微镜观察拍照，并通过肺充血、肺出血、炎性细胞浸润、肺泡壁厚度等方面进行肺病理损伤评分计算。
(3)血气分析检测：小鼠经注射250μl 1％戊巴比妥钠(PBS配制)麻醉后，用1ml注射器(1mg/ml肝素钠抗凝)从腹主动脉抽取500μl左右动脉血，通过血气分析仪进行检测，分析血氧饱和度和氧合指数。
结果表明，组2表现出典型急性肺损伤病理特征，肺泡结构破坏出血、肺泡壁明显增厚、有炎症细胞浸润，胎盘多能干细胞制剂注射组小鼠肺组织结构损伤程度明显降低，表现为肺泡壁变薄、肺泡结构改善、炎症细胞浸润减少(如图1中A所示)，肺组织损伤评分(lung injury scores)结果显示胎盘多能干细胞制剂注射组对ALI的病理学改善均有显著差异(如图1中B所示)。此外，血气分析检测表明，胎盘多能干细胞制剂注射能够显著改善血氧饱和度和氧合指数、改善肺功能(如图2所示)。
最后，还需要注意的是，以上列举的仅是本发明的若干个具体实施例。显然，本发明不限于以上实施例，还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形，均应认为是本发明的保护范围。
Claims (5)
- 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用。
- 如权利要求1所述的应用，其特征在于所述胎盘多能干细胞制剂按如下方法制备：将贴壁培养的胎盘多能干细胞用0.25％胰蛋白酶-EDTA消化液进行消化，生理盐水洗涤后，再用生理盐水悬浮，即为胎盘多能干细胞制剂。
- 如权利要求2所述的应用，其特征在于所述胎盘多能干细胞为贴壁生长的成纤维样细胞，表达CD73、CD90和CD105，不表达CD14、CD19、CD34、CD45和HLA-DR。
- 如权利要求2所述的应用，其特征在于所述胎盘多能干细胞制剂中细胞浓度为(2～6)×10 7个/ml。
- 如权利要求1所述的应用，其特征在于所述药物为治疗急性肺病理损伤或治疗肺功能损伤的药物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711373750.3A CN108030791A (zh) | 2017-12-19 | 2017-12-19 | 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 |
| CN201711373750.3 | 2017-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019119819A1 true WO2019119819A1 (zh) | 2019-06-27 |
Family
ID=62099884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2018/099147 WO2019119819A1 (zh) | 2017-12-19 | 2018-08-07 | 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108030791A (zh) |
| WO (1) | WO2019119819A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108030791A (zh) * | 2017-12-19 | 2018-05-15 | 杭州易文赛生物技术有限公司 | 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 |
| CN109646457A (zh) * | 2018-12-20 | 2019-04-19 | 杭州易文赛生物技术有限公司 | 一种脐带间充质干细胞在制备治疗急性肺损伤药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016086020A1 (en) * | 2014-11-24 | 2016-06-02 | Cytostormrx Llc | Encapsulated stem cells for the treatment of inflammatory disease |
| CN106038597A (zh) * | 2016-05-27 | 2016-10-26 | 遵义医学院附属医院 | 间充质干细胞在制备治疗急性肺损伤制剂中的应用 |
| CN108030791A (zh) * | 2017-12-19 | 2018-05-15 | 杭州易文赛生物技术有限公司 | 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105769910B (zh) * | 2016-04-15 | 2020-01-03 | 遵义医学院附属医院 | 一种人羊膜间充质干细胞的应用 |
-
2017
- 2017-12-19 CN CN201711373750.3A patent/CN108030791A/zh active Pending
-
2018
- 2018-08-07 WO PCT/CN2018/099147 patent/WO2019119819A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016086020A1 (en) * | 2014-11-24 | 2016-06-02 | Cytostormrx Llc | Encapsulated stem cells for the treatment of inflammatory disease |
| CN106038597A (zh) * | 2016-05-27 | 2016-10-26 | 遵义医学院附属医院 | 间充质干细胞在制备治疗急性肺损伤制剂中的应用 |
| CN108030791A (zh) * | 2017-12-19 | 2018-05-15 | 杭州易文赛生物技术有限公司 | 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| LEE, JW.: "Potential application of mesenchymal stem cells in acute lung injury", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 9, 1 October 2009 (2009-10-01), pages 1259 - 1270, XP055521705, ISSN: 1471-2598, doi:10.1517/14712590903213651 * |
| LIU TING ET AL.: "The Inflammation Regulation Function of human Placenta-derived Mesenchymal stem cells on patients with acute lung injury", JOURNAL OF BAOTOU MEDICAL COLLEGE, vol. 33, no. 10, 15 October 2017 (2017-10-15), pages 74 - 76, ISSN: 1006-740X * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108030791A (zh) | 2018-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104666344B (zh) | 间充质干细胞外泌体在制备治疗肺纤维化的药物制剂中的应用 | |
| CN106714781A (zh) | 涉及外排体的方法和组合物 | |
| JP5112336B2 (ja) | 臍帯血から分離または、増殖された細胞を含む進行性、慢性肺疾患治療用組成物 | |
| CN112121063B (zh) | 外泌体在制备治疗肺纤维化的药物中的应用 | |
| CN105687244B (zh) | 一种制剂、其制备方法及其应用 | |
| WO2020135199A1 (zh) | 心肌细胞制剂及其制备方法和应用 | |
| EP3957718A1 (en) | Method for resisting aging and enhancing stem characteristics of human mesenchymal stem cells | |
| WO2019119819A1 (zh) | 一种胎盘多能干细胞制剂在制备治疗急性肺损伤药物中的应用 | |
| CN109646457A (zh) | 一种脐带间充质干细胞在制备治疗急性肺损伤药物中的应用 | |
| CN111518758A (zh) | 一种用于肺病治疗的脐带间充质干细胞及其制备方法 | |
| TW201704466A (zh) | 間質幹細胞、其純株化擴張之方法、其分離方法及其應用 | |
| Lorenzini et al. | Stem cells for end stage liver disease: how far have we got? | |
| WO2018025976A1 (ja) | 多能性幹細胞による虚血再灌流肺障害の軽減及び治療 | |
| WO2017012226A1 (zh) | 间质干细胞、其克隆源性扩增的方法、其分离方法及其应用 | |
| KR101834800B1 (ko) | 심장 조직-유래 세포 | |
| CN106701669A (zh) | 临床治疗用间充质干细胞及其制备方法和用途 | |
| WO2020228819A1 (zh) | 一种临床级自体支气管基底层细胞及回输制剂和制备工艺 | |
| Abreu et al. | Serum from patients with asthma potentiates macrophage phagocytosis and human mesenchymal stromal cell therapy in experimental allergic asthma | |
| CN103558392B (zh) | 一种基于炎症反应的抗动脉粥样硬化药效评价方法 | |
| CN114099534A (zh) | 高表达miR-214的外泌体及其制备方法与应用 | |
| Lin et al. | CD34− human placenta-derived mesenchymal stem cells protect against heat stroke mortality in rats | |
| KR20150020112A (ko) | 메트포민이 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| KR20140104377A (ko) | 줄기세포를 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물 | |
| CN104120104B (zh) | 一种cd34+细胞的生产方法 | |
| CN114010658B (zh) | TREM2hi巨噬细胞在制备治疗心脏功能障碍药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18890172 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18890172 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18/12/2020) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18890172 Country of ref document: EP Kind code of ref document: A1 |